PARP1 and female reproductive organ cancer: The last decade has seen a paradigm shift in systemic therapy for gynecological cancers, driven by the introduction of targeted agents, particularly immune checkpoint inhibitors and poly-ADP-ribose polymerase (PARP) inhibitors.